Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatePRNewsWire • 08/06/25
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate UpdatePRNewsWire • 05/08/25
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia AreataPRNewsWire • 04/30/25
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia AreataPRNewsWire • 04/16/25
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate UpdatePRNewsWire • 03/11/25
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology MeetingPRNewsWire • 03/08/25
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual MeetingPRNewsWire • 02/28/25
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia AreataPRNewsWire • 02/10/25
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences ConferencePRNewsWire • 02/04/25
Q32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia TreatmentInvestors Business Daily • 12/11/24
Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development ProgramPRNewsWire • 12/10/24
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatePRNewsWire • 11/07/24
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation ConferencePRNewsWire • 11/05/24
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024PRNewsWire • 10/14/24
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 91.69%: Read This Before Placing a BetZacks Investment Research • 08/12/24
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic DermatitisPRNewsWire • 07/09/24